Acetylcholinesterase inhibitors in cognitive impairment in Huntington’s disease: A brief review

Joe John Vattakatuchery, Renjith Kurien

Abstract
Huntington’s disease (HD) is a neurodegenerative disease associated with cognitive deficits. Cognitive dysfunction may be present in the early stages of the disease, even before the onset of motor symptoms. The cognitive dysfunction includes executive dysfunction, psychomotor symptoms, visuospatial deficits, perceptual deficits, memory loss and difficulty learning new skills. Acetylcholinesterase inhibitors have shown good effect in the treatment of other types of dementia and it is postulated that it might delay cognitive decline in HD. We reviewed the evidence for Acetylcholinesterase inhibitors in the treatment of cognitive deficits in Huntington’s disease. We identified 6 articles that investigated the role of Acetylcholinesterase inhibitors for treatment of cognitive deficits in Huntington’s disease. Following the review, the authors concluded that there is limited evidence for the use of Acetylcholinesterase inhibitors for cognitive impairment in HD.

INTRODUCTION
The clinical description of Huntington’s disease (HD) was reported by George Huntington in 1872 and led to increased recognition of the condition[1]. The prevalence of the illness is about 5.70 per 100000 births[2]. HD is characterised by movement disorder, cognitive deficits and psychiatric symptoms. HD is a progressive neurodegenerative autosomal dominant disorder caused by a single defective gene on chromosome 4. In HD, mutation of HTT gene leads to abnormal CAG trinucleotide repeat[3]. A larger number of repeat is associated with earlier onset of the illness[4].

The clinical features of HD frequently include cognitive dysfunction[5]. Cognitive dysfunction may be present in the early stages of the disease, even before the onset of motor symptoms[6]. Cognitive dysfunction includes executive dysfunction, psychomotor symptoms, visuospatial deficits, perceptual deficits, memory loss and difficulty learning new skills. Cognitive dysfunction lead to frontal and subcortical dementia[7]. There are structural and

Core tip: The evidence for Acetylcholinesterase inhibitors in the treatment of cognitive decline and dementia associated with Huntington’s disease is reviewed in this article. Six articles were identified that investigated the role of Acetylcholinesterase inhibitors for treatment of cognitive deficits in Huntington’s disease (HD). We concluded that there is limited evidence for the use of Acetylcholinesterase inhibitors for cognitive impairment in HD.

Vattakatuchery JJ, Kurien R. Acetylcholinesterase inhibitors in cognitive impairment in Huntington’s disease: A brief review. World J Psychiatr 2013; 3(3): 62-64 Available from: URL: http://www.wjgnet.com/2220-3206/full/v3/i3/62.htm DOI: http://dx.doi.org/10.5498/wjp.v3.i3.62
while conclusions about it is difficult to make any worth 3 completed the trial) and did not have a control group, of UHDRS. As the study had only four subjects (only was no improvement in motor and functional subscales. There results showed an improvement in cognitive and behavior- were evaluated at baseline and 26 wk of therapy. The re- were used to assess change in cognitive function. They Mental State Examination (MMSE) and Trail making test. Huntington's Disease Rating Scale (UHDRS), Mini Mental State Examination (MMSE) and Trail making test. There was no improvement in motor and functional subscales of UHDRS. As the study had only four subjects (only 3 completed the trial) and did not have a control group, it is difficult to make any worthwhile conclusions about the efficacy of Acetylcholinesterase inhibitors from this study.

Petrikis et al.\(^\text{11}\) report a case of a 35-year-old male patient with HD who presented with symptoms of an acute psychotic episode. He was evaluated using Positive and Negative Syndrome Scale, Extrapyramidal Symptom Rating Scale and MMSE. He was initially treated with Haloperidol Decanoate and after a month this was changed to Galantamine. The authors report good improvement of psychotic symptoms and chorea on Galantamine but there was no improvement in his cognitive functioning (Table 1).

de Tommaso et al.\(^\text{14}\) conducted a single centre; short term randomised open labelled controlled study in twenty one patients affected by HD. Patients received Rivastigmine as an add-on therapy for 8 mo. Fourteen patients were allocated to Rivastigmine group and 7 to control group. Patients were evaluated using MMSE, Marsden and Quinn Chorea Severity Scale and Abnormal Involuntary Movement Scale. Patients on Rivastigmine approached statistically significant improvement (\(P = 0.06\)) in MMSE score compared to their basal score. Statistical significance was not achieved when intervention group was compared to control group during repeated measures of other clinical features in the 8 mo of the study. Rivastigmine did not appear to reduce hyperkinesia in the intervention group. This study has several drawbacks. The study had only 21 patients and the lack of statistically significant results may be due to the lack of power. Secondly, MMSE was used to assess cognitive function. This may not be an appropriate tool because MMSE fails to capture frontal lobe dysfunc- tion, which is typically impaired in HD.

Cubo et al.\(^\text{15}\) investigated the effect of Donepezil on motor and cognitive function in HD. Thirty patients were randomly allocated to active or placebo groups. Drug and placebo were administered for 6 wk (Donepezil 5 mg) and donepezil was increased to 10 mg at 6 wk for further 6 wk. Patients were evaluated at baseline, 6 and 12 wk.

**REVIEW OF LITERATURE**

**Search strategy**

We used Medline, EMBASE and PsychINFO databases and used key terms such as Acetylcholinesterase inhibitors, HD, Huntington's dementia, Donepezil, Galantamine and Rivastigmine. The bibliographies of all identified articles and previously published reviews were scanned for additional studies.

**Description of identified studies**

Six studies were identified that investigated the effect of Acetylcholinesterase inhibitors inhibitors in HD.

Fernandez et al.\(^\text{13}\) conducted an open label trial of 8 patients with HD and prescribed Donepezil. Two patients had slight improvement in memory and concentration at 5 mg/d. There was no statistically significant improvement at 6 wk from baseline scores on all neuropsychological tests. Due to 4 patients dropping out, analysis at 12 wk was not done due to lack of statistical power.

Rot et al.\(^\text{25}\) investigated the effect of Rivastigmine on four symptomatic HD patients (3 females, 1 male). Unified Huntington's Disease Rating Scale (UHDRS), Mini Mental State Examination (MMSE) and Trail making test were used to assess change in cognitive function. They were evaluated at baseline and 26 wk of therapy. The results showed an improvement in cognitive and behavioral parts of UHDRS, MMSE and Trail making test. There was no improvement in motor and functional subscales of UHDRS. As the study had only four subjects (only 3 completed the trial) and did not have a control group, it is difficult to make any worthwhile conclusions about functional brain changes in HD that correlate to cogni- tive deficits\(^\text{8}\). Decreased Acetyl Choline levels have been noted in HD patients\(^\text{9,10}\).

---

**Table 1 Trials and reports of Acetyl cholinesterase use in Huntington’s disease**

| Ref. | Design | Medication used | Outcome measures | Result |
|------|--------|-----------------|------------------|--------|
| Fernandes et al.\(^\text{13}\) | Open labelled study | Donepezil | UHDRS, MMSE, Wechsler memory scale-III, Symbol Digit, Odd Man Out test, Hopkins Verbal Learning test | No statistical significance between mean scores at baseline and 6 wk on all neuropsychological tests. |
| Rot et al.\(^\text{25}\) | Longitudinal study | Rivastigmine | UHDRS, MMSE, Trail making test | Improvement on cognitive tests and behavioural part of UHDRS |
| Petrikis et al.\(^\text{11}\) | Case report | Galantamine | PANSS | Improvement on PANSS and ESRS but no improvement on MMSE |
| de Tommaso et al.\(^\text{14}\) | Prospective, open labelled randomized controlled trial | Rivastigmine | MMSE, Marsden and Quinn Chorea Severity Scale, Total Functional Capacity score, Abnor- mal Involuntary Movement scale | Improvement on MMSE compared to baseline |
| Cubo et al.\(^\text{15}\) | Randomized controlled trial | Donepezil | UHDRS, Alzheimer's Disease Assessment Scale, Sickness Impact Profile | No significant improvement except for improvement on UHDRS-FAS (Verbal Fluency test) |
| de Tommaso et al.\(^\text{14}\) | Randomized, blinded, controlled, open labelled prospective | Rivastigmine | MMSE, Marsden and Quinn Chorea Severity scale, Total Functional Capacity score, Abnor- mal Involuntary Movement scale | Slight increase in MMSE but not statistically significant |

UHDRS: Unified Huntington’s Disease Rating Scale; MMSE: Mini Mental State Examination; PANSS: Positive and negative syndrome scale; ESRS: Extrapyramidal symptom rating scale.
Unified Huntington’s Disease Rating Scale (UHDRS) was used to evaluate motor performance. Cognitive function was assessed using cognitive section of Alzheimer’s Disease Assessment Scale and UHDRS. Chorea change was used as primary outcome measure and cognitive function change was used as a secondary outcome measure. There was no significant improvement in chorea measure between the two groups. There was no significant improvement in any measure of cognition except of a trend towards improvement on UHRDS-FAS (Verbal Fluency test). The study was not designed to evaluate change in cognitive function on donepezil as chorea change was used as primary outcome measure. One of the exclusion criteria was dementia with HD.

de Thommaso et al\(^1\) reported the results of two-year follow up of HD patients on Rivastigmine therapy previously evaluated in a short-term study. This was a long term, open-label, blinded, controlled study. The evaluation was carried out in a final group of 11 treated patients and 6 non-treated patients. The results showed a slight increase in MMSE scores in patients Rivastigmine compared to non-treated group who exhibited a mild decline in MMSE scores. However, these differences were not statistically significant. This study has similar drawbacks as those raised about their original study.

**CONCLUSION**

Cognitive deficits due to Huntington’s disease are common and cause significant morbidity. Cubo et al\(^1\) postulates that the role of cholinergic system in cognitive deficits may be less relevant than previously thought and cholinergic stimulation may not be beneficial. There are no adequately powered well-designed trials to support the use of Acetylcholinesterase inhibitors in treating cognitive impairment in HD\(^1\). Review of existing studies suggests that there is limited evidence for the use of Acetylcholinesterase inhibitors in the treatment of cognitive deficits associated with HD. Large randomised controlled trials with adequate follow up are needed to investigate the efficacy of Acetylcholinesterase inhibitors in HD.

**REFERENCES**

1. Lanska DJ. George Huntington (1850-1916) and hereditary chorea. J Hist Neurosci 2000; 9: 76-89 [PMID: 11232552]
2. Pringsheim T, Wiltshire K, Day L, Dykeman J, Steeves T, Jette N. The incidence and prevalence of Huntington’s disease: a systematic review and meta-analysis. Mov Disord 2012; 27: 1083-1091 [PMID: 22692795 DOI: 10.1002/mds.25075]
3. Ross CA, Tabrizi SJ. Huntington’s disease: from molecular pathogenesis to clinical treatment. Lancet Neurol 2011; 10: 83-98 [PMID: 2163446 DOI: 10.1016/S1474-4422(10)70245-3]
4. Snell RG, MacMillan JC, Cheadle JP, Fenton I, Lazarou LP, Davies P, MacDonald ME, Gusella JF, Harper PS, Shaw DJ. Relationship between trinucleotide repeat expansion and phenotypic variation in Huntington’s disease. Nat Genet 1993; 4: 393-397 [PMID: 8401588 DOI: 10.1038/ng0893-393]
5. Rosenblatt A, Leroi I. Neuropsychiatry of Huntington’s disease and other basal ganglia disorders. Psychosomatics 2000; 41: 24-30 [PMID: 10665265 DOI: 10.1016/S0033-3182(00)71170-4]
6. Phillips W, Shannon KM, Barker RA. The current clinical management of Huntington’s disease. Mov Disord 2008; 23: 1491-1504 [PMID: 18581443 DOI: 10.1002/mds.21971]
7. Novak MJ, Tabrizi SJ. Huntington’s disease: clinical presentation and treatment. Int Rev Neurobiol 2011; 98: 297-323 [PMID: 21907093 DOI: 10.1016/B978-0-12-381328-2.00013-4]
8. Montoya A, Price BH, Menear M, Lepage M. Brain imaging and cognitive dysfunctions in Huntington’s disease. J Psychiatry Neurosci 2006; 31: 21-29 [PMID: 16496032]
9. Spokes EG. Neurochemical alterations in Huntington’s chorea: a study of post-mortem brain tissue. Brain 1980; 103: 179-210 [PMID: 6102490 DOI: 10.1093/brain/103.1.179]
10. Lange KW, Javoy-Agid F, Agid Y, Jenner P, Marsden CD. Brain muscarinic cholinergic receptors in Huntington’s disease. J Neuro 1992; 239: 103-104 [PMID: 1552417 DOI: 10.1007/BF00862983]
11. Fernandez HH, Friedman JH, Grace J, Beason-Hazen S. Donepezil for Huntington’s disease. Mov Disord 2000; 15: 173-176 [PMID: 10634264]
12. Rot U, Kobal J, Sever A, Pirtosek Z, Mesec A. Rivastigmine in the treatment of Huntington’s disease. Eur J Neurol 2002; 9: 689-690 [PMID: 12453090 DOI: 10.1016/j.ejneurol.2002.00447_4.x]
13. Petrikis P, Andreou C, Pachas A, Bozikas VP, Karavatos A. Treatment of Huntington’s disease with galantamine. Int Clin Psychopharmacol 2004; 19: 49-50 [PMID: 15101572]
14. de Tommaso M, Specchio N, Sciriuchio V, Difruscolo O, Specchio LM. Effects of rivastigmine on motor and cognitive impairment in Huntington’s disease. Mov Disord 2004; 19: 1516-1518 [PMID: 15398067 DOI: 10.1002/mds.20235]
15. Cubo E, Shannon KM, Tracy D, Jaglin JA, Bernard BA, Wuu J, Leurgans SE. Effect of donepezil on motor and cognitive function in Huntington disease. Neurology 2006; 67: 1268-1271 [PMID: 17030764 DOI: 10.1212/01.wnl.0000238106.10423.00]
16. de Tommaso M, Difruscolo O, Sciriuchio V, Specchio N, Livrea P. Two years’ follow-up of rivastigmine treatment in Huntington disease. Clin Neuropharmacol 2007; 30: 43-46 [PMID: 17227969 DOI: 10.1097/01.wnl.0000240945.44370.0f]
17. Mestre T, Ferreira J, Coelho MM, Rosa M, Sampaio C. Therapeutic interventions for symptomatic treatment in Huntington’s disease. Cochrane Database Syst Rev 2009; CD006456 [PMID: 19588393 DOI: 10.1002/14651858.CD006456.p]

P-Reviewer: Orlacchio A  S-Editor: Song XX  L-Editor: A E-Editor: Wang CH
